269 related articles for article (PubMed ID: 34344244)
1. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
2. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
3. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
Okura M; Ida N; Yamauchi T
Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
[TBL] [Abstract][Full Text] [Related]
4. Human Lymphoid Tissues Harbor a Distinct CD69+CXCR6+ NK Cell Population.
Lugthart G; Melsen JE; Vervat C; van Ostaijen-Ten Dam MM; Corver WE; Roelen DL; van Bergen J; van Tol MJ; Lankester AC; Schilham MW
J Immunol; 2016 Jul; 197(1):78-84. PubMed ID: 27226093
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib resistance can be reversed by induced expression of plasma cell maturation markers in a mouse in vitro model of multiple myeloma.
Stessman HA; Mansoor A; Zhan F; Linden MA; Van Ness B; Baughn LB
PLoS One; 2013; 8(10):e77608. PubMed ID: 24204892
[TBL] [Abstract][Full Text] [Related]
6. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
[TBL] [Abstract][Full Text] [Related]
7. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
[TBL] [Abstract][Full Text] [Related]
8. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
Kurihara K; Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Hatta Y; Nakayama T; Takei M
Med Oncol; 2019 Jul; 36(9):75. PubMed ID: 31342211
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of interleukin 12 and CD56+ lymphocyte cells in pediatric hematopoietic stem cell transplantation for early diagnosis of acute graft versus host disease.
Tootoonchian R; Pak F; Ardekani AM; Sehati N; Abedi-Valugerdi M; Kokhaei P
Transpl Immunol; 2016 Nov; 39():25-29. PubMed ID: 27751764
[TBL] [Abstract][Full Text] [Related]
10. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Mathew P; Ahmann GJ; Witzig TE; Roche PC; Kyle RA; Greipp PR
Br J Haematol; 1995 Jun; 90(2):459-61. PubMed ID: 7540857
[TBL] [Abstract][Full Text] [Related]
12. CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
Del Poeta G; Del Principe MI; Zucchetto A; Luciano F; Buccisano F; Rossi FM; Bruno A; Biagi A; Bulian P; Maurillo L; Neri B; Bomben R; Simotti C; Coletta AM; Dal Bo M; de Fabritiis P; Venditti A; Gattei V; Amadori S
Haematologica; 2012 Feb; 97(2):279-87. PubMed ID: 21993667
[TBL] [Abstract][Full Text] [Related]
13. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].
Zhang CX; Wang HT; Zhang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):827-831. PubMed ID: 34105479
[TBL] [Abstract][Full Text] [Related]
15. [Significance of CD138/syndecan-1 for multiple myeloma immunophenotypes].
Zhuang JL; Wang X; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1023-7. PubMed ID: 16403272
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of cell morphology and immunophenotypic characteristics in 47 cases of multiple myeloma].
Su XD; Lin R; Xu XL; Chen X; Zhan WL; Zheng JP; Fan CL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):137-41. PubMed ID: 25687061
[TBL] [Abstract][Full Text] [Related]
17. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB; Sachs Z; Noble-Orcutt KE; Mitra A; Van Ness BG; Linden MA
Leuk Lymphoma; 2017 Aug; 58(8):1931-1940. PubMed ID: 27981867
[TBL] [Abstract][Full Text] [Related]
19. [Immunophenotype characteristics in multiple myeloma cells and their significance].
Sun Y; Fang MY; Liu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):381-4. PubMed ID: 20416173
[TBL] [Abstract][Full Text] [Related]
20. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
